Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes
Abstract
Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide MR) remain an important option in the treatment algorithms of type 2 diabetes mellitus (DM2). A large observational international study EASYDia in real clinical practice, assessing effectiveness of gliclazide MR 60 mg in patients with long-term DM2 on standard glucose-lowering therapy, showed that step-by-step intensification of therapy with gliclazide MR 60mg allows to achieve and maintain the target values of glycemia, with good tolerability even in maximum doses, low risk of hypoglycemia and no weight gain.
About the Authors
Natalia Р. TrubitsynaEndocrinology Research Centre
Russian Federation
MD, PhD, leading research associate
Competing Interests:
Трубицына Н.П. выступала с постерным докладом на ежегодном конгрессе EASD в 2015 г. по результатам международного, открытого, наблюдательного, нерандомизированного, несравнительного исследования в реальной повседневной клинической практике EASYDia.
Marina V. Shestakova
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor
Competing Interests:
Шестакова М.В. получала вознаграждение за лекции от фармацевтической группы Сервье, была координатором в России международного, открытого, наблюдательного, нерандомизированного, несравнительного исследования в реальной повседневной клинической практике EASYDia, реализованного при поддержке фармацевтической группы Сервье, которая не оказывала влияния на конечные результаты исследования.
References
1. Advance Collaborative Group; Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: https://doi.org/10.1056/NEJMoa0802987
2. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37(8):2359–2365. doi: https://doi.org/10.2337/dc14-0199
3. Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89(2):126–133. doi: https://doi.org/10.1016/j.diabres.2010.05.012
4. National Institute for Health and Care Excellence (NICE) Internal Clinical Guidelines Team. Type 2 diabetes in adults (Clinical Guideline Update NG28). London, UK: National Institute for Health and Care Excellence; 2017.
5. Gordon J, McEwan P, Evans M, et al. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017;19(5):644–653. doi: https://doi.org/10.1111/dom.12867
6. Rutten GE, De Grauw WJ, Nijpels G, et al. [NHG-Standaard Diabetes mellitus type 2 (derde herziening). (In Dutch).] Huisarts Wet. 2013;56(10):512–525.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379. doi: https://doi.org/10.2337/dc12-0413
8. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes. 2016;40(6):484–486. doi: https://doi.org/10.1016/j.jcjd.2016.09.003
9. World Health Organization. Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Geneva: World Health Organization; 2018.
10. Royal Australian College of General Practitioners (RACGP) and Diabetes Australia. General practice management of type 2 diabetes 2016-2018. East Melbourne, Vic: Royal Australian College of General Practitioners; 2016. 232 p.
11. SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. JEMDSA. 2017;22 Suppl 1:S1–S196.
12. Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab. 2015;19(5):577–596. doi: https://doi.org/10.4103/2230-8210.163171
13. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555. doi: https://doi.org/10.1038/bjc.2013.725
14. Ruiz M. Diamicron (gliclazide) MR: the secretagogue with clinical benefits beyond insulin secretion. Medicographia. 2013;35(1):81–89.
15. Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND // Сахарный диабет. – 2011. – Т.14. –№3 – С. 96–102. [Shestakova MV, Vikulova OK. The results of open observational trial DIAMOND. Diabetes mellitus. 2011;14(3):96–102. (In Russ).] doi: https://doi.org/10.14341/2072-0351-6232
16. Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract. 2016;112:50–56. doi: https://doi.org/10.1016/j.diabres.2015.11.001
17. Leiter LA, Shestakova MV, Satman I. Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetol Metab Syndr. 2018;10(1):30. doi: https://doi.org/10.1186/s13098-018-0331-8
18. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: https://doi.org/10.1056/NEJMoa1307684
19. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi: https://doi.org/10.1056/NEJMoa1515920
20. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi: https://doi.org/10.1056/NEJMoa1305889
21. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094. doi: https://doi.org/10.1056/NEJMc1600827
22. Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. doi: https://doi.org/10.2337/dc16-0621
23. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588. doi: https://doi.org/10.1161/CIRCULATIONAHA.114.010389
24. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: https://doi.org/10.1056/NEJMoa1501352
25. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: https://doi.org/10.1056/NEJMoa1607141
26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: https://doi.org/10.1056/NEJMoa1603827
27. Neal B, Perkovic V, Mahaffey KW, et al. Canaglilozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: https://doi.org/10.1056/NEJMoa1611925
28. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498. doi: https://doi.org/10.1007/s00125-018-4729-5
29. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–326. doi: https://doi.org/10.2147/VHRM.S64038
30. Clemens KK, McArthur E, Dixon SN, et al. The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide. Can J Diabetes. 2015;39 Suppl 4:32–40. doi: https://doi.org/10.1016/j.jcjd.2015.09.087
31. Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3(1):e000108. doi: https://doi.org/10.1136/bmjdrc-2015-000108
32. Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. Diabet Med. 2016;33(10):1315–1329. doi: https://doi.org/10.1111/dme.13080
33. Aravind SR, Al Tayeb K, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237–1242. doi: https://doi.org/10.1185/03007995.2011.578245
34. Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109(2):226–232. doi: https://doi.org/10.1016/j.diabres.2015.04.030
Review
For citations:
Trubitsyna N.Р., Shestakova M.V. Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. Diabetes mellitus. 2019;22(2):159-164. (In Russ.)
Views:
2205
Email this article 
